CPT® Code 90291

1. Indications

The administration of human cytomegalovirus immune globulin (CMV-IgIV) is indicated for specific clinical scenarios where protection against cytomegalovirus is necessary. The following conditions warrant the use of this immunizing agent:

• Prevention of CMV infection in high-risk individuals, particularly those undergoing organ transplantation or hematopoietic stem cell transplantation, where exposure to CMV can lead to severe complications.
• Post-exposure prophylaxis for individuals who have been exposed to CMV, especially in immunocompromised patients or those with weakened immune systems.

2. Procedure

The procedure for administering human cytomegalovirus immune globulin (CMV-IgIV) involves several critical steps to ensure safety and efficacy. The following procedural steps outline the process:

• Step 1: Patient Assessment - Prior to administration, a thorough assessment of the patient’s medical history and current health status is conducted. This includes evaluating any previous reactions to immune globulin products and determining the appropriateness of CMV-IgIV for the patient’s specific situation.
• Step 2: Preparation of the Product - The CMV-IgIV is prepared for intravenous administration. This involves checking the product for integrity, ensuring it is within the expiration date, and following aseptic techniques to maintain sterility.
• Step 3: Administration - The immune globulin is administered intravenously, typically through a dedicated IV line. The infusion rate is carefully monitored and adjusted based on the patient’s tolerance and any potential adverse reactions. It is essential to observe the patient closely during the infusion for any signs of allergic reactions or side effects.
• Step 4: Post-Administration Monitoring - After the infusion, the patient is monitored for a specified period to ensure there are no immediate adverse reactions. Vital signs are checked, and the patient is observed for any signs of discomfort or complications.

3. Post-Procedure

Following the administration of CMV-IgIV, patients may require specific post-procedure care to ensure their safety and well-being. It is important to monitor the patient for any delayed reactions or side effects that may occur after the infusion. Patients should be advised to report any unusual symptoms, such as fever, rash, or difficulty breathing, to their healthcare provider. Additionally, follow-up appointments may be scheduled to assess the effectiveness of the treatment and to monitor the patient’s overall health status. Documentation of the administration, including the lot number of the immune globulin and any reactions observed, is essential for compliance and future reference.